ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

Zacks11-19

Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with Biosion for global rights...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484278921?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","is_english":true,"pubTime":"2024-11-19 22:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484278921","market":"us","top_or_hot":-1,"title":"ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs","media":"Zacks","content":"<div>\n<p>Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with Biosion for global rights...</p>\n\n<a href=\"https://finance.yahoo.com/news/acrs-stock-licensing-deal-biosion-141900379.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 22:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/acrs-stock-licensing-deal-biosion-141900379.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with Biosion for global rights...</p>\n\n<a href=\"https://finance.yahoo.com/news/acrs-stock-licensing-deal-biosion-141900379.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/acrs-stock-licensing-deal-biosion-141900379.html","article_id":"2484278921","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484278921","pubTimestamp":1732025940,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement withBiosion for global rights to two of the latter’s pipeline candidates, BSI-045B and BSI-502.Biosion’s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis. Results from a completed phase IIa proof-of-concept study by Biosion demonstrated that BSI-045B has a pharmacodynamic, safety and efficacy profile indicative of its potential as a best-in-class therapy.Several mid-stage studies of the candidate are ongoing in China for severe asthma and chronic rhinosinusitis with nasal polyps, aiming to accelerate potential proof-of-concept demonstrations for additional indications. The other investigational candidate, per the terms of the licensing deal, is BSI-502, a potential best-in-class, novel bispecific antibody that is","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4578":"CAR-T","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","PFE":"辉瑞","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","ALLO":"Allogene Therapeutics Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","GILD":"吉利德科学","LU0122379950.USD":"贝莱德世界健康科学A2","BK4505":"高瓴资本持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4581":"高盛持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","ACRS":"Aclaris Therapeutics","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4583":"猴痘概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4585":"ETF&股票定投概念"},"translate_title":"ACRS与Biosion就两种免疫学药物达成许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"GILD":1,"PFE":1,"ACRS":1},"content_text":"Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with Biosion for global rights (excluding Greater China) to two of the latter’s pipeline candidates, BSI-045B and BSI-502.\nBiosion’s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis. Results from a completed phase IIa proof-of-concept study by Biosion demonstrated that BSI-045B has a pharmacodynamic, safety and efficacy profile indicative of its potential as a best-in-class therapy.\nSeveral mid-stage studies of the candidate are ongoing in China for severe asthma and chronic rhinosinusitis with nasal polyps, aiming to accelerate potential proof-of-concept demonstrations for additional indications. The other investigational candidate, per the terms of the licensing deal, is BSI-502, a potential best-in-class, novel bispecific antibody that is directed against both TSLP and IL4R, which is currently in the preclinical stage. However, both candidates are yet to be evaluated by regulatory authorities.\nYear to date, shares of Aclaris have skyrocketed 199% against the industry’s 6% decline.\nImage Source: Zacks Investment Research\nPer management, the licensing deal with Biosion concludes Aclaris’ strategic review process to maximize shareholders’ value. The addition of these two potentially transformative treatments is expected to complement Aclaris’ existing ITK inhibitor portfolio, resulting in a pipeline of differentiated assets that target multiple high-value immunologic and respiratory indications.\nAclaris’ pipeline currently comprises several candidates undergoing clinical development across various stages for skin disease and cancer indications.\nCash Consideration for the Deal Between ACRS and Biosion\nPer the terms of the licensing agreement, Aclaris is liable to make a $30 million upfront payment to Biosion for the transfer of global rights to BSI-045B and BSI-502. Biosion is also entitled to receive $4.5 million for certain development costs and $6.2 million for certain development and drug product reimbursement from Aclaris.\nMoreover, Aclaris is liable to make additional payments of up to $125 million upon the achievement of specified regulatory milestones and up to $795 million upon the achievement of specified sales milestones. Biosion also remains eligible to receive a tiered low-to-mid single-digit royalty based upon a percentage of annual net sales from Aclaris.\nIn a separate press release, ACRS announced a private offering for gross proceeds of approximately $80 million, which is expected to close on or about Nov. 19, 2024, subject to the satisfaction of customary closing conditions. The company intends to use the proceeds from this transaction to fund the research and development of its pipeline and for general corporate purposes.\nManagement believes that this private placement will strengthen Aclaris’ balance sheet and provide enough flexibility to support its strategic growth while maintaining its cash runway into 2028.\n\nAclaris Therapeutics, Inc. Price and Consensus\n\nAclaris Therapeutics, Inc. price-consensus-chart | Aclaris Therapeutics, Inc. Quote\n\nACRS’ Zacks Rank and Stocks to Consider\nAclaris currently carries a Zacks Rank #3 (Hold).\nSome better-ranked pharma stocks are Allogene Therapeutics ALLO, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nOver the past 60 days, Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 33% year to date.\nAllogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.\nOver the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.88 per share for 2024, while that for 2025 has increased from $2.85 to $2.92. PFE shares have lost 13.6% year to date.\nPfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.\nOver the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.28 per share for 2024 while that for 2025 has increased from $7.24 to $7.40. GILD shares have risen 9.2% year to date.\nGilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nAclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484278921"}